Building ABC - Aspen’s Biological Capability
Aspen’s Capabilities across the Vaccines Value Chain
Globally and especially in LMICs and across Africa

Aspen is a partner with demonstrated ability to adopt different technologies at speed and to international standard.

Aspen is seeking to build a portfolio of vaccines (and other biologicals) utilising diverse technology platforms.

Aspen has a substantial international footprint covering Africa, Asia, Europe and Oceania, in many countries being a leading manufacturer of medicines, including specialty sterile presentations.

Aspen, since inception, has been a company committed to global health and equity, starting with accessible ARV supplies through to most recently supply COVID-19 vaccine.
COVID19 has demonstrated the need for global sterile capacity, especially in Africa. The end state capacity is significant and will not only be a large contributor to global supply but will be extremely meaningful to meeting the needs of Africa and other LMIC’s.
50-100 Million Syringes available

- 2 BFS lines
- 1 Bag line
- 4 inspection lines
- 5 packaging lines
- 3 sterile filling lines

QA / QC
Aspen’s Global Footprint

- UK/Nordics
- France/BeNeLux
- Germany/Austria/Switzerland
- Italy
- Poland/Czechia
- Turkey
- United Arab Emirates
- Russia
- China
- Philippines
- Malaysia
- Taiwan
- South Africa
- Tanzania
- Kenya
- Namibia
- Botswana
- Ghana
- Australia
- Canada
- Mexico
- Brazil
- Caricam
- Andean
- Tanzania
- Kenya
- Namibia
- Botswana
- Ghana
- South Africa
Offers and Asks

Aspen Offers

• Established capacity at scale
• Proven capability for technology partners
• Opportunity for innovators to continue to provide DS/DP
• SRA experience including biologicals and vaccines
• A portfolio in line with African Union, Africa CDC and PAVM priorities
• Options for emergency use vaccines
• An international commercialisation footprint

Aspen’s Asks

• Consolidated African demand sustained over a 5 year time horizon
• Continental/regional and national procurement policies that mandate African manufacturing
• Funding to support ‘at scale’ pricing for a 5 year period but not at ‘rent seeking’ levels
• Recognition that African needs manufacturing expertise across the value chain ie not just end-end; input as well as later stage manufacture, and commercialisation should be valued
• Policies that support African manufacturer collaborations
• Trade policies that support cross border supply
• Harmonisation/mutual recognition of regulatory and release requirements